Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

2: Tranexamic Acid Is Associated With Decreased Intraoperative Blood Loss And Wound Healing Complication Rate In Penile Inversion Vaginoplasty

Gunderson K., Edalatpour A., Wirth P., Rose K., Gast K.

Retrospective Study with a reported sample of 56 on Chronic Wound, published in Plast Reconstr Surg Glob Open (2021) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Plast Reconstr Surg Glob Open (2021)
Reported sample size
56
Source database
Europe PMC
PMCID
PMC8312833

Abstract (original English)

Purpose: Penile inversion vaginoplasty (PIV) is the most common gender affirming genital procedure for transfeminine patients. The purpose of this study was to investigate the impact of tranexamic acid (TXA), an antifibrinolytic, on bleeding and bleeding-related complications in vaginoplasty surgery. Methods: Retrospective chart review was performed on patients undergoing PIV from February 2018 through March 2020 by the senior author (K.G.) at the University of Wisconsin Hospital and Clinics. Patients who received TXA received a combination of topical and intravenous TXA. Data collected includes patient demographics (age, body mass index, race, comorbidities, and tobacco and illicit drug use), intraoperative data (duration of surgery, estimated blood loss, fluid administration, TXA use and dose, and complications), and postoperative data (drain output, complications within 30 days, and revision surgery). Subgroup analysis on the effect of TXA was performed using independent sample t-test. Results: Seventy-four patients were included in this study with 56 patients receiving TXA and 18 patients who had surgery prior to initiation of TXA protocol. There were no thromboembolic events observed in the TXA or the non-TXA group. Ninety percent of all complications were Clavien-Dindo Grade 1 and did not require intervention. There was a significantly lower EBL in the TXA group compared

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research